NIH R01 · 2025
Our previous groundbreaking research, published in 2020 and 2023, unveiled the remarkable synergy achieved by combining oral Vancomycin with radiation therapy (RT) or Chimeric Antigen Receptor T-cell therapy (CART) in enhancing the antitumor response. This innovative approach exploited Vancomycin's unique ability to selectively deplete specific gut microbiota while promoting the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs) post-therapy. Notably, our preclinical studies demonstrated significant improvements in antitumor effects across multiple mouse models, including metastatic melanoma, lung cancer, and lymphoma. Building upon these groundbreaking…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.